Participants in this research will be randomly assigned to receive either REGN7508 or a placebo. This is a double-blind study, meaning that neither the participants nor the researchers know which treatment is being administered. During the course of the study, the effectiveness of the medication in preventing blood clots and its impact on the risk of bleeding will be monitored. This includes looking for any significant bleeding events to ensure the safety of the treatment.

Participants in the study will be assigned to receive either the study drug REGN7508, which is a Factor XI monoclonal antibody delivered through an intravenous injection, or acetylsalicylic acid, also known as aspirin. Some participants may also receive a placebo. The study is designed so that neither the researchers nor the participants know which treatment is being administered during the process.

During the study, the way the body absorbs and uses the medication is monitored under different conditions. This involves looking at the pharmacokinetics, which is the study of how a substance moves through the body over time. One part of the study examines the medication when taken in a fasted state, meaning without any food in the stomach. Another part examines the effects of a high-fat, high-calorie meal on how the drug is absorbed by the body.

The study will involve healthy volunteers who will take a single dose of each version of the apixaban tablet on separate occasions. Between taking the two different versions, there will be a waiting period to make sure the first dose is completely cleared from the body before the second dose is given. The volunteers will not eat before taking the medicine to see how the body absorbs it under fasting conditions. This type of study design is called a crossover study because each person will receive both versions of the medicine at different times.

During the study, blood samples will be collected from the volunteers at different times after they take the medicine. These samples will be used to measure how much apixaban is in the blood and how long it stays there. The researchers will look at specific measurements to compare the two versions, including the highest amount of medicine in the blood and the total amount of medicine absorbed over time. This information will help determine if the test version works as well as the reference version.

The study will give participants a single dose of BAY 3018250 starting at a low dose of 150 milligrams and increasing up to 1200 milligrams, or they will receive placebo. The medicine will be given as an infusion, which means it will slowly drip into a vein over a period of time. The study will check for any unwanted effects that might happen during or after the treatment, and it will measure the highest amount of medicine in the blood and how long it stays in the body.

This is the first time this medicine is being tested in people, so the study will only include healthy men between 18 and 45 years old. Participants will be randomly assigned to receive either the study medicine or placebo, and they will not know which one they are getting, though the study team will know. The study will track how participants feel and any side effects they may experience to help researchers understand if this treatment could be safe to test further in people who have had a stroke.

The purpose of the study is to determine how effective REGN7508 is at preventing blood clots after knee replacement surgery when compared to the standard treatments. The medication will be given either through an intravenous injection into a vein or as an injection under the skin. Some patients will receive apixaban tablets to take by mouth, while others will receive enoxaparin as an injection under the skin.

During the study, doctors will monitor patients for signs of blood clots and bleeding. They will also check how well the body tolerates the new medication and whether the body develops any response to it. The study will look for different types of blood clots, including deep venous thrombosis (blood clots in deep veins) and pulmonary embolism (blood clots in the lungs).

The purpose of the study is to evaluate how well REGN9933 and REGN7508 work in preventing blood clots and to assess their safety. Participants in the study will receive either REGN9933, REGN7508, or a placebo. The treatments are given as a powder mixed into a solution and administered through an intravenous infusion, which means they are delivered directly into the bloodstream. The study will monitor participants for any side effects and measure the concentration of the drugs in the body over time.

Throughout the study, the incidence of blood clots and any bleeding events will be closely observed. The study aims to provide valuable information on the effectiveness and safety of these treatments in preventing blood clots in patients with a PICC. This research could potentially lead to new ways to prevent venous thromboembolism in patients who require long-term intravenous access.

The purpose of the study is to evaluate how these medications perform in patients undergoing a procedure called Balloon Pulmonary Angioplasty (BPA). This procedure is used to open up blocked blood vessels in the lungs. The study will look at the occurrence of bleeding and lung injury within 24 hours after the procedure. Participants will receive one of the medications or a placebo, and their health will be monitored to see how well the medications work and how safe they are.

The study will take place over a period of time, with participants receiving treatment for up to 30 days. During this time, researchers will collect data on any complications, such as bleeding or lung issues, as well as other health outcomes like allergic reactions, kidney problems, and hospitalizations. The goal is to better understand which medication is most effective and safe for patients with CTEPH or CTED undergoing BPA.

The purpose of the study is to evaluate how well REGN7508 works in preventing blood clots after knee surgery. Participants in the study will receive either REGN7508 or enoxaparin sodium. Some participants may receive a placebo, which is a substance with no active medication. The study will monitor participants for any blood clots or bleeding events for about 12 days after surgery, and overall health will be observed for approximately 75 days.

Throughout the study, participants will have regular check-ups to ensure their safety and to monitor the effects of the treatment. The study aims to provide valuable information on the effectiveness and safety of REGN7508 in preventing blood clots in patients undergoing knee replacement surgery.

The purpose of the study is to see if using FDG PET/CT can find more hidden cancers compared to a more limited cancer screening approach. Patients who are 50 years or older and have recently been diagnosed with their first unprovoked VTE will be part of this study. The study will last for one year, during which participants will undergo the FDG PET/CT scan and follow-up checks to monitor for any signs of cancer. The study will also compare the results of this new screening method with traditional methods to see which is more effective in detecting cancer early.

Participants will receive an injection of a special substance called Gallium (68Ga) Chloride, which helps highlight areas of interest in the body during the scan. This substance is part of a product known as GalliaPharm. Some participants may receive a placebo instead. The study aims to improve cancer detection in patients with unprovoked VTE and to understand the potential benefits and costs of using advanced imaging techniques like FDG PET/CT in routine cancer screening. The findings from this study may help develop better screening strategies for future patients.

The purpose of the study is to evaluate the effectiveness of using tinzaparin sodium for four months to prevent blood clots in patients with metastatic colorectal cancer who are starting their first line of treatment. This treatment may include chemotherapy, targeted therapy, or immunotherapy. The study will monitor patients for any blood clot events, whether they show symptoms or are found incidentally, during this period.

Participants in the study will receive either the medication or a placebo, and their health will be closely monitored throughout the trial. The study aims to gather information on how well the medication works in preventing blood clots in this specific group of patients. The trial is expected to continue until April 2025, providing valuable insights into the management of blood clots in patients with metastatic colorectal cancer.

The purpose of the study is to evaluate how well REGN9933 works in preventing blood clots after knee surgery. Participants in the study will receive either REGN9933, enoxaparin sodium, or a placebo. The study will last for about 12 days, during which the occurrence of blood clots and any side effects will be monitored. The study will also look at the levels of REGN9933 in the blood and any changes in blood clotting times.

Throughout the study, participants will be closely monitored for any major bleeding or other side effects. The study aims to provide valuable information on the safety and effectiveness of REGN9933 in preventing blood clots after knee replacement surgery, potentially offering a new option for patients undergoing this procedure.